| Literature DB >> 12789623 |
Abstract
Lilly is developing LY-354740, the lead compound in a series of derivatives of the metabotropic glutamate receptor group II agonist L-CCG-1, for the potential treatment of anxiety [212536], [276941], [276942].Entities:
Mesh:
Substances:
Year: 2003 PMID: 12789623
Source DB: PubMed Journal: IDrugs ISSN: 1369-7056